Yours, Mine and Ours: Supreme Court Speaks on the Patentability of Human Genes
1h 1m
Created on November 14, 2014
Intermediate
Overview
Last summer, the Supreme Court issued its decision in Association for Molecular Pathology, et al. v. US Patent and Trademark Office, Myriad Genetics, et al, S. Ct. 2107 (2013), regarding whether human genes are patentable. Although the Court held that isolated, naturally-occurring DNA segments are unpatentable products of nature, that is not the end of the story for the biotech industry. The Court also held that non-naturally occurring DNA segments are patentable.
This course explores the Courts’ decision and its effect on the current set of court challenges: the patentability of DNA segments in the context of primers (DNA strands that jumpstart DNA replication) and probes (which are primers with an attachment). The course also evaluates the new US Patent Office Guidelines issued on March 4, 2014.
Learning Objectives:
I. Understand the Supreme Court decision in Association for Molecular Pathology, et al. v. US Patent and Trademark Office, Myriad Genetics, et al, S. Ct. 2107 (2013)
II. Grasp the patentability of DNA segments in the context of primers (DNA strands that jumpstart DNA replication) and probes (which are primers with an attachment)
III. Evaluate the new US Patent Office Guidelines issued on March 4, 2014
Gain access to this course, plus unlimited access to 1,800+ courses, with an Unlimited Subscription.
Explore Lawline Subscriptions